Download Files:
Products Details
Product Description
– Lusutrombopag-d13 is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
Web ID
– HY-19883S
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C29H19D13Cl2N2O5S
References
– [1]Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
Molecular Weight
– 604.63
SMILES
– O=C(O)/C(C)=C/C1=C(Cl)C=C(C(NC2=NC(C3=CC=CC([C@@H](OC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])C)=C3OC)=CS2)=O)C=C1Cl
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Isotope-Labeled Compounds;Thrombopoietin Receptor
Pathway
– Immunology/Inflammation;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
